Pre-surgery postbiotic pill may cut colon cancer operation risks
NCT ID NCT07268846
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether taking a postbiotic supplement (butyrate) for 7 days before colorectal cancer surgery can lower the chance of complications like infections or bowel issues. Researchers will compare complication rates in 164 adults who get the supplement versus those who don't. The goal is to see if this simple, low-cost approach can make recovery safer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- butyrate (a postbiotic dietary supplement)
- What this could lead to
- If it works, this could point toward a simple, low-cost way to lower complication rates after colorectal cancer surgery.
- What could go wrong
- This is a small, early-stage trial testing a dietary supplement. The effect on complications may be small or absent, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 164 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Individuals diagnosed with malignant neoplasm of the large intestine, specifically adenocarcinoma. * Patients over 18 years of age, of both sexes. * Patients who agree to participate in the study and sign the informed consent form. Exclusion Criteria: * Emergency or urgent surgeries. * Cytoreductive surgeries involving intraoperative intraperitoneal chemotherapy. * Extended surgeries for the treatment of recurrent tumors.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer (colon cancer, breast cancer, lymphoma, chronic lymphoma leukemia, multiple myeloma) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
A.C.Camargo Cancer Center
RECRUITINGSão Paulo, São Paulo, 01509-010, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug put to the test against Hard-to-Treat GI cancers
- Can berry compounds tame inflammation during colorectal cancer care?
- Can a vaccine stop GI cancers from returning?
- Blood test guides immunotherapy for hidden cancer cells
- Can blocking a cancer cell survival protein open a new path for colorectal cancer?
- Can blocking a DNA repair protein make immunotherapy work better against colorectal cancer?